Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of desmopressin cas 16679-58-6 in China. Welcome to wholesale bulk high quality desmopressin cas 16679-58-6 for sale here from our factory. Good service and reasonable price are available.
The molecular formula of Desmopressin is C46H64N14O12S2, CAS 16679-58-6, with a molecular weight of approximately 1069.22. Usually a white powder, but its appearance may vary depending on the production process and purity. It is an artificially synthesized cyclic nine peptide mainly used to treat diseases such as central diabetes insipidus and nocturnal enuresis in children aged five and above. When storing, it should be refrigerated at low temperature, preferably freeze-dried at -20 ℃ and sealed, and placed in a dark and dry environment.
Our Products Form
Desmopressin COA
Desmopressin, as an artificially synthesized antidiuretic hormone analog, has important value in the clinical treatment of companion animals such as cats and dogs. It activates the V2 receptor in the renal collecting duct, promotes membrane transport of aquaporin-2 (AQP2), significantly enhances the reabsorption capacity of renal tubules for water, thereby reducing urine volume and increasing urine osmotic pressure.
Alternative treatment for central diabetes insipidus (CDI)
Central diabetes insipidus is a disease caused by insufficient secretion of antidiuretic hormone (ADH) due to damage to the hypothalamic pituitary system, leading to polyuria, polyphagia, and low specific gravity urine. By exogenous supplementation of ADH activity, it has become the core drug for CDI treatment.
1. Treatment plan for dogs
Dosage and administration method: Oral dosage is 0.1-0.2mg/time, 2-3 times a day; The intramuscular injection dose is 0.05-0.1 μ g/kg, 1-2 times a day. In cases of CDI secondary to elderly dogs or pituitary tumors, dose adjustment should be combined with imaging examinations (such as MRI).
Efficacy monitoring: Within 24 hours of treatment, urine output can be reduced by 50% -70%, and urine osmotic pressure can increase from<100mOsm/kg to>600mOsm/kg. Regular monitoring of blood sodium concentration (target value 140-150mmol/L) is necessary to avoid hyponatremia (blood sodium<135mmol/L).
Long term management: Idiopathic CDI dogs require lifelong medication, while secondary cases of trauma or tumors may be relieved with the control of the primary disease.
2. Treatment plan for cats
Dosage and administration method: Oral dose is 0.025-0.05mg/time, twice a day; Conjunctival sac instillation (nasal drops) 2-4 drops/time, 1-2 times a day.
Sensitive breeds such as Geran Shepherd and Mini Poodle need to be monitored more closely.
Efficacy evaluation: Within 3 days of treatment, there was a significant reduction in water intake and an increase of over 50% in urine concentration. Primary CDI in cats requires lifelong medication, while secondary cases (such as traumatic brain injury and pituitary tumors) may be discontinued with treatment for the primary disease.
Risk prevention and control: Cats are more sensitive to hyponatremia and should strictly limit their water intake (≤ 40ml/kg/day during treatment), and monitor symptoms of water poisoning such as vomiting and ataxia.
Diagnostic tool for renal urine concentration function test
It can be used to distinguish cerebral diabetes insipidus (CDI) from renal diabetes insipidus (NDI), and its principle is to evaluate renal concentration ability through exogenous ADH stimulation.
1. Experimental process
Water prohibition stage: Animals are prohibited from water for 8-12 hours until their urine density stabilizes or their body weight decreases by 5%.
Drug stimulation: intramuscular injection of MINIRIN (dog: 2 μ g/15kg body weight; Cat: 1 μ g/5kg body weight).
Monitoring indicators: Collect urine every 2 hours after injection to detect urine osmotic pressure and specific gravity.
2. Diagnostic criteria
CDI: After injection, the urinary osmotic pressure significantly increased (>600mOsm/kg), indicating normal renal response to ADH and the problem lies in the ADH secretion pathway.
NDI: There was no significant change in urine osmotic pressure after injection (<300mOsm/kg), indicating insensitivity of the kidneys to ADH, which may be caused by congenital receptor defects or secondary kidney injury.
3. Clinical significance
Dogs such as German Shepherd and Siberian Huskies are prone to primary NDI, and treatment plans need to be developed after excluding CDI through experiments.
Cats: Primary NDI in kittens (2-6 months old) may be genetically related, and the test results directly affect reproductive risk assessment.
Hemostasis and Prevention of Hemorrhagic Diseases
Desmopressin promotes the release of coagulation factor VIII and von Willebrand factor (vWF) from endothelial cells, increasing the concentration of these factors in plasma and thus exerting hemostatic effects.
1. Treatment of Von Willebrand (vWD)
Indications: Type I vWD patients, especially suitable for bleeding control after surgery or trauma.
Dosage regimen: Intravenous injection of 0.5-1 μ g/kg, used 30 minutes before surgery, can shorten bleeding time by 30% -50%.
Efficacy monitoring: Evaluate the effect through vWF antigen detection and bleeding time measurement, and if necessary, combine blood transfusion therapy.
2. Liver related coagulation disorders
Mechanism: Cirrhotic animals suffer from coagulation factor deficiency due to decreased liver synthesis function, and MINIRIN can temporarily correct platelet dysfunction.
Application scenario: Before surgery for hepatic encephalopathy in dogs and cats, intravenous injection of 0.3 μ g/kg can reduce intraoperative bleeding by 20% -40%.
3. Intervention for drug-induced bleeding
Case: Platelet dysfunction caused by aspirin overdose, oral administration of desmopresin 0.1mg/time can shorten bleeding time.
Caution: It should be used in combination with vitamin K to avoid relying solely on ADH analogues.
Regulation of brain injury/postoperative polyuria
Animals with brain injury or surgery often exhibit polyuria symptoms, which can be maintained by reducing urine output to maintain fluid balance.
1. Traumatic brain injury (TBI)
Application timing: Start treatment when polyuria (urine volume>50ml/kg/day) occurs 24-48 hours after TBI.
Dose adjustment: The initial dose is 0.05 μ g/kg, administered every 12 hours, and adjusted to 0.1 μ g/kg based on urine output.
Monitoring focus: blood sodium and intracranial pressure should be jointly detected to avoid water retention aggravating brain edema.
2. Postoperative diabetes insipidus
Surgical types: Pituitary tumor resection, ventriculoperitoneal shunt, etc.
Treatment plan: Immediately inject 0.5 μ g/kg intravenously after surgery, and then switch to oral maintenance.
Prognostic assessment: 90% of cases restore fluid balance within 72 hours, and long-term prognosis depends on controlling the primary disease.
Adjuvant treatment for special disease states
Uremic bleeding: Animals with chronic renal failure are prone to bleeding due to abnormal platelet function, and desmopresin can temporarily improve coagulation function.
Dosage: Intravenous injection of 0.2 μ g/kg, once daily, in combination with erythropoietin.
Diabetes ketoacidosis (DKA): Hyperosmolar state leads to ADH resistance, and desmopresin can help correct polyuria.
Attention: Blood sugar and acidosis should be controlled before initiating ADH treatment.
Actual case
Canine CDI treatment: A 5-year-old male Golden Retriever developed CDI due to pituitary adenoma, with a daily urine output of 12L. After using desmopresin (0.1 μ g/kg, twice daily), urine output decreased to 4L, blood sodium concentration increased from 125mmol/L to 142mmol/L, and symptoms improved significantly.
Surgical hemostasis for feline vWD: A 3-year-old female plush cat requires sterilization surgery due to type I vWD.
Preoperative use of desmopresin (0.1 μ g/kg, intravenous injection) resulted in a 50% reduction in intraoperative bleeding and good postoperative recovery.
Polyuria after canine brain injury: An 8-year-old male Labrador Retriever suffered brain injury due to a car accident and developed polyuria (8L per day) after surgery. After using desmopresin (0.05 μ g/kg, twice daily), urine output decreased to 3L and blood sodium concentration remained normal.
A method for solid-phase cyclization synthesis of Desmopressin vasopressin solves the problems of large amount of waste liquid generated by air liquid-phase oxidation, outdated production process, low efficiency, and excessive by-products of iodine as an oxidant in existing technologies.
The following are some chemical equations involved in the above methods:
The chemical equation for coupling amino acids:
Gly: COOH + NH2 resin → COO resin + NH3
Arg (pbf): COOH + NH2 resin → COO resin + NH3
Pro: COOH + NH2 resin → COO resin + NH3
Cys (Trt): COOH + NH2 resin → COO resin + NH3
Asn (Trt): COOH + NH2 resin → COO resin + NH3
Gln (Trt): COOH + NH2 resin → COO resin + NH3
Phe: COOH + NH2 resin → COO resin + NH3
Tyr (tBu): COOH + NH2 resin → COO resin + NH3
Mpa (Trt): COOH + NH2 resin → COO resin + NH3
The chemical equation for removing protective groups:
Cys (Trt): COO resin + C2HF3O2 → COOH + TrtF
Mpa (Trt): COO resin + C2HF3O2 → COOH + TrtF
The chemical equation for solid ring reaction:
Cyclic peptide formation: C30H26NO5R → RinkAmide cyclic peptide resin
The chemical equation for cracking:
Depressin formation: RinkAmide cyclic peptide resin → C46H64N14O12S2
The synthesis process steps are as follows:
RinkAmide AM resin was coupled with 9 amino acids in sequence, namely Fmoc Gly OH, Fmoc D-Arg (pbf) - OH, Fmoc Pro OH, Fmoc Cys (Trt) - OH, Fmoc Asn (Trt) - OH, Fmoc Gln (Trt) - OH, Fmoc Phe OH, Fmoc Tyr (tBu) - OH, Mpa (Trt) - OH. The specific coupling conditions can refer to relevant literature or experimental operation manuals.
After coupling is completed, clean the resin to remove unreacted amino acids and impurities.
Rinse the resin with 1% TFA/DCM solution to remove the protective group Trt on Cys (Trt) and Mpa (Trt).
After rinsing, clean the resin to remove residual TFA and DCM.
React the processed resin with oxidizing reagents to form cyclic peptides from amino acids. The specific reaction conditions and selection of oxidation reagents can refer to relevant literature or experimental operation manuals.
After the reaction is completed, clean the resin to remove unreacted oxidizing agents and impurities.
Decompose the cyclic peptide resin to obtain deaminovasopressin. The specific cracking conditions can refer to relevant literature or experimental operation manuals.
After the lysis is completed, the desmopressin vasopressin is purified to remove impurities and by-products.
Expanding Clinical Applications
Its core indications cover central diabetes insipidus, pediatric nocturnal enuresis, mild hemophilia A and von Willebrand disease. In recent years, new indications for elderly populations such as adult nocturia have been added, securing its stable position in clinical guidelines. The approval of new formulations including oral solutions has enabled precise dose titration across all age groups, significantly improving adherence in pediatric and elderly patients, and further unlocking niche scenarios such as rare diseases and postoperative diabetes insipidus.
Iterative Upgrading of Formulations and Technologies
Development has evolved from traditional tablets, nasal sprays and injections toward novel drug delivery systems such as oral solutions, oral dissolving films and long-acting sustained-release microspheres, addressing pain points including difficult dose adjustment and inconvenient administration. Long-acting formulations reduce dosing frequency, support home-based chronic disease management, and drive higher penetration in home care settings.
Dual Drivers of Market and Policy
The global market is growing at a compound annual growth rate (CAGR) of approximately 7%–9%, with the Asia-Pacific region leading the expansion (CAGR 5.5%–7%+). The Chinese market is expected to exceed 1.8 billion yuan by 2030. Centralized procurement has promoted price rationalization and improved accessibility. With generics and innovative formulations developing in parallel, enterprises with integrated API and formulation capabilities will hold a competitive advantage.
Coexistence of Challenges and Opportunities
Safety risks such as hyponatremia require continuous monitoring, and intensifying competition has put pressure on prices. However, population aging, increased attention to rare diseases and the popularization of primary care provide support for long-term growth, pointing to a generally positive outlook.
Hot Tags: desmopressin cas 16679-58-6, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, LONG R3 IGF I CAS 143045 27 6, Kisspeptin powder, Best Growth Hormone Releasing Peptide CAS 87616 84 0, Tesamorelin CAS 218949 48 5, GLP 1 Peptide CAS 87805 34 3, Melanotan 2 Powder